Dr. Michael Gilio, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 145 Helen St, Hamden, CT 06514 Phone: 203-248-5466 Fax: 203-248-5466 |
News Archive
A study conducted by researchers at Thomas Jefferson University, Philadelphia, and published Tuesday, July 27, 2004, in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the incidence of menstrual associated migraines (MAM) in women who took the medication preventively, in advance of anticipated onset of headache.
Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease. Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a revolutionary new aerosol delivery system. It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.
GlaxoSmithKline plc (GSK) and Theravance, Inc., a privately-held pharmaceutical company, announced today that they have entered into an innovative broad-based strategic alliance to develop and commercialise novel medicines across a variety of important therapeutic areas, including bacterial infection, respiratory, urinary incontinence and gastrointestinal.
A conference to explore how the future of the American auto industry could affect United Auto Workers (UAW) patients and their physicians and dentists will be presented by the Michigan State Medical Society and the Michigan Dental Association on Thursday, Sept. 17, from Noon to 4:30 p.m. at the Rock Financial Showplace in Novi.
The first-ever detailed examination of a country's investment in research on childhood and adolescent cancers was released today by the Canadian Cancer Research Alliance (CCRA) and the Canadian Partnership Against Cancer (the Partnership).
› Verified 7 days ago